Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 trial

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 6, 2011, Pages 462-466

  Zinzani, Pier Luigi ^a   Pellegrini, Cinzia ^a   Gandolfi, Letizia ^a   Stefoni, Vittorio ^a   Quirini, Federica ^a   Derenzini, Enrico ^a   Broccoli, Alessandro ^a   Argnani, Lisa ^a   Pileri, Stefano ^a   Baccarani, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Diffuse large B cell lymphoma; Elderly patients; Lenalidomide; Relapsed refractory; Rituximab

Indexed keywords

LENALIDOMIDE; RITUXIMAB;

AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER RELAPSE; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84857654592     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.02.001     Document Type: Article

References (29)

1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-42. (Pubitemid 34438862)
2. Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with goodprognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the Mab- Thera International Trial (MInT) Group. Lancet Oncol 2006; 7:379-91.
3. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23:5027-33. (Pubitemid 46224009)
4. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9:105-16.
5. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24:3121-7. (Pubitemid 46638950)
6. Cunningham D, Smith P, Mouncey P, et al. A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma [abstract]. J Clin Oncol 2009; 27(suppl 15; abstr): 8506.
7. Delarue R, Tilly H, Salles G, et al. R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: results of the interim analysis of the LNH03-6B GELA study. Blood 2009; 114(abstr):406.
8. Tilly H, Dreyling M; ESMO Guidelines Working Group. Ann Oncol 2010; 21 (suppl 5):v172-4.
9. El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 2007; 18:1363-8. (Pubitemid 47305011)
10. López A, Gutiérrez A, Palacios A, et al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol 2008; 80:127-32.
11. Corazzelli G, Capobianco G, Arcamone M, et al. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplantineligible patients with refractory/relapsing B-cell lymphoma. Cancer Chemother Pharmacol 2009; 64:907-16.
12. Zhu D, Corral LG, Fleming YW, et al. Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells throughNKcell activation. Cancer Immunol Immunother 2008; 7:1849-59.
13. Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20 tumor cells. Clin Cancer Res 2008; 14:4650-7.
14. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:4952-7.
15. Haioun C, Czuczman MS, Vose JM, et al. Patients with relapsed or refractory diffuse large-B-cell lymphoma treated with oral lenalidomide monotherapy: results from the international study NHL-003 [abstract]. Haematologica 2009; 94(suppl 2; abstr): 0982.
16. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31:1860-1.
17. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. Lyon: International Agency for Research on Cancer, 2008.
18. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer, 1981; 47:207-14. (Pubitemid 11167383)
19. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38:143-51.
20. A'Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med 2001; 20:859-66. (Pubitemid 32249085)
21. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-86. (Pubitemid 350002966)
22. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53:457-81.
23. Morschhauser F, Illidge T, Huglo D, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 2007; 110: 54-8. (Pubitemid 47026818)
24. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96:1259-66. (Pubitemid 30658452)
25. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:667-75. (Pubitemid 46224166)
26. Coiffier B, Haioun N, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92:1927-32. (Pubitemid 28446681)
27. Fosså A, Santoro A, Hiddemann W, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3786-92.
28. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 2005; 11: 5984-92 (Pubitemid 41170330)
29. Bartlett JB, Wu L, Adams M, et al. Lenalidomide and pomalidomide strongly enhance tumor cell killing in vitro during antibody-dependent cellular cytotoxicity (ADCC) mediated by trastuzumab, cetuximab and rituximab. J Clin Oncol 2007; 25(suppl 15; abstr):3023.